(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 March 2008 (20.03.2008)

PCT

(10) International Publication Number
WO 2008/031875 A1

(51) International Patent Classification:
C07D 473/00 (2006.01) *A61P 11/00* (2006.01)
A61K 31/495 (2006.01) *A61P 29/00* (2006.01)

(21) International Application Number:
PCT/EP2007/059666

(22) International Filing Date:
13 September 2007 (13.09.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
06120706.4 14 September 2006 (14.09.2006) EP

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FAIRHURST, Robin Alec** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). **TAYLOR, Roger John** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB).

(74) Agent: **STUART, Graham**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report*

[Continued on next page]

(54) Title: ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS



(I)

(57) Abstract: A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, formula (1), or stereoisomers or pharmaceutically acceptable salts thereof, wherein A, U^1, U^2, R^{1a}, R^{1b}, R^2 and R^3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A_{2A} receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

WO 2008/031875 A1

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*